Alshehri Nadiyah, Ahmed Anwar E, Yenugadhati Nagarajkumar, Javad Sundas, Al Sulaiman Khalid, M Al-Dorzi Hasan, Aljerasiy Majed, Badri Motasim
Pharmaceutical Care Department, Ministry of National Guard- Health Affairs, Riyadh, Saudi Arabia.
Department of Epidemiology & Biostatistics, College of Public Health and Health Informatics, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Ther Clin Risk Manag. 2020 Oct 14;16:979-987. doi: 10.2147/TCRM.S266295. eCollection 2020.
Vancomycin is one of the most common therapeutic agents for treating gram-positive infections, particularly in critically ill patients. The aim of this study was to identify factors associated with initial therapeutic vancomycin trough levels and mortality in a tertiary-care intensive care unit (ICU).
This retrospective study evaluated 301 adult ICU patients admitted to King Abdulaziz Medical City in Riyadh between October 1, 2017 and December 31, 2018 with confirmed gram-positive infections and received intravenous vancomycin. Vancomycin trough levels of 15-20 mg/L for severe infections and 10-15 mg/L for less severe infections were considered therapeutic.
The patients were relatively older with a mean age of 60 (SD ±20) years. Initial vancomycin trough levels were therapeutic in 168 (55.8%). Factors associated with initial therapeutic vancomycin trough levels were female gender (adjusted odds ratio [aOR]=2.575), older age (aOR=1.024), receiving a loading dose (aOR=2.445), having bacteremia (aOR=2.061), and high platelet count (aOR=1.003). On the other hand, the increase of estimated glomerular filtration rate (eGFR) (aOR=0.993) and albumin levels (aOR=0.944) were associated with lower odds of initial therapeutic vancomycin trough levels. Factors associated with higher mortality were female gender (adjusted hazard ratio [aHR]=2.630), increased body weight (aHR=1.021), cancer (aHR=3.451), and high APACHE II score (aHR=1.068).
The study identified several factors associated with achieving initial therapeutic vancomycin trough levels (i.e. older age, female gender, receiving a loading dose, bacteremia, high platelets count, low eGFR and albumin level). These factors should be considered in the dosing of vancomycin in critically ill patients with gram-positive infections.
万古霉素是治疗革兰氏阳性菌感染最常用的药物之一,尤其是在重症患者中。本研究的目的是确定三级医疗重症监护病房(ICU)中与初始治疗性万古霉素谷浓度及死亡率相关的因素。
这项回顾性研究评估了2017年10月1日至2018年12月31日期间入住利雅得阿卜杜勒阿齐兹国王医疗城的301例确诊革兰氏阳性菌感染并接受静脉注射万古霉素的成年ICU患者。严重感染时万古霉素谷浓度为15 - 20 mg/L,不太严重感染时为10 - 15 mg/L被视为治疗有效。
患者年龄相对较大,平均年龄为60(标准差±20)岁。168例(55.8%)患者的初始万古霉素谷浓度达到治疗水平。与初始治疗性万古霉素谷浓度相关的因素有女性(调整优势比[aOR]=2.575)、年龄较大(aOR=1.024)、接受负荷剂量(aOR=2.445)、患有菌血症(aOR=2.061)和血小板计数高(aOR=1.003)。另一方面,估计肾小球滤过率(eGFR)升高(aOR=0.993)和白蛋白水平升高(aOR=0.944)与初始治疗性万古霉素谷浓度达到治疗水平的几率较低相关。与较高死亡率相关的因素有女性(调整风险比[aHR]=2.630)、体重增加(aHR=1.021)、癌症(aHR=3.451)和高急性生理学与慢性健康状况评分系统(APACHE II)评分(aHR=1.068)。
该研究确定了几个与达到初始治疗性万古霉素谷浓度相关的因素(即年龄较大、女性、接受负荷剂量、菌血症高血小板计数、低eGFR和白蛋白水平)。在革兰氏阳性菌感染的重症患者中使用万古霉素时应考虑这些因素。